Inducing Apoptosis of NCI-H157 Human Lung Carcinoma Cells via Activation of Caspase Cascade by Combination Treatment with Arsenic Trioxide and Sulindac

Tuberculosis and Respiratory Diseases

Volumn 56, Issue 4, 2004, Pages 381-392

  Kim, Hak Ryul ^a   Yang, Sei Hoon ^a,b   Jeong, Eun Taik ^a  

^a Wonkwang University   (South Korea)

^b Wonkwang University Hospital   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; Lung Cancer Cell line; Sulindac

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; FAS LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL VIABILITY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME MECHANISM; ENZYME SUBSTRATE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; PROMYELOCYTIC LEUKEMIA; PROTEIN FAMILY; TIME; WESTERN BLOTTING;

EID: 2442461209     PISSN: 03780066     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2004.56.4.381     Document Type: Article

References (33)

1. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenecity of high-arsenicartesian well water: Multiple risk factors and related malignant neoplasm of blackfoot disease. Arteriosclerosis 1988;8:452-60.
2. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 1992;66:888-92.
3. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992;12:170-1.
4. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
5. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529-38.
6. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, et al. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 1999;4:33-7.
7. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1992;445:59-62.
8. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999;265:400-4.
9. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide incuces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999;82:286-92.
10. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35:1258-63.
11. Thun MJ, Namboodiri NM, Health CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
12. Harris RE, Nambodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
13. Scheinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
14. Smalley WE, Dubois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
15. Dannenberg AJ, Zakim D. Chemoprevention of colon-rectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 1999;26:499-504.
16. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
17. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanism underlying nonsteroidal and inflammatory drug-mediated apoptosis. Proc Natl Acad Sci 1998;95:681-6.
18. Klampfer L, Cammenga J, Wisniewski HG, Nimer SD. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999;93:2386-94.
19. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-9.
20. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Invest Drugs 1999;8:1623-38.
21. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4.
22. Williams GT. Apoptosis in the immune system. J Pathol 1994;173:1-4.
23. Cohen JJ. Apoptosis: the physiologic pathway of cell death. Hosp Pract 1993;28:35-43.
24. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
25. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia: arsenic trioxide induces NB4 cell apoptosis with downregualation of Bcl-2 expression and modulation of PML-BARα /PML proteins. Blood 1996;88:1052-61.
26. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-64.
27. Jung BH, Park C, Kim HR, Park MR. Arsenic trioxide induces apoptosis of HL-60 cells via activation of intrinsic caspase protease with mitochondrial dysfunction. Cancer Res and Treat 2002;34:308-15.
28. Huang S, Huang CF, Lee T. Induction of mitosis-mediated apoptosis by sodium arsenite in Hela S3 cers. Biochem Pharmacol 2000;60:771-80.
29. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, P21, and apoptosis. Cancer Res 2000;60:3065-71.
30. Torrance CJ, Jackson PF, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
31. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of NSAIDs. Eur J Cancer 1998;34:1250-9.
32. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59:6178-84.
33. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11.